Help patients get answers and support for complex questions
with a trusted partner in genetic testing and counseling.
Access to Expert Genetic Counseling
Integrated Genetics has the largest national genetic counseling network. We offer both
in-person and easy access telegenetic genetic counseling that allows patients to interact
directly and “face-to-face” with our genetic counselors. Our counselors take complex genetic
data and turn it into practical, understandable, information and options, which can help
in making important, highly personal healthcare choices.
From a Company You Know and Trust
informaSeq, an advanced and accurate prenatal test
prenatal testing directed by board-certified molecular geneticists as early as
10 weeks’ gestational age
 Accurate
 Testing
performed via deep sequencing, which increases detection, even in samples with
a lower fraction of fetal DNA fragments
 Dual
Threshold resulting stratifies risk prediction
 Quick
resulting – 5-7 business days
Genetic counseling, to give your patients vital information
Genetic Risk Assessment
Patient Education
Patient Information
Coordinated
Patient Care
We evaluate reproductive and family history, review test results
and medical records, and identify genetic risk factors that can
affect the patient or offspring.
 More
We address any identified genetic risk factors, discuss the
disorder in question, including etiology, heritability, and clinical
implications, and explain testing and procedure options.
Integrated Genetics, an experienced partner
than 140 Integrated Genetics Genetic Counselors to help patients review results,
identify risk factors, and make more informed decisions
 Convenient
 Over
 A
We support the decision-making process by providing patients
clinical information and referrals to community resources.
Telegenetic Counseling services providing access for more patients
25 years of genetic testing expertise
complete menu of screening and diagnostic tests focused on women’s reproductive health
 Contracts
 Over
with more than 400 payors nationwide
1,700 patient service centers for convenient access to sample collection
We provide a summary report to the referring physician and
follow-up genetic counseling if indicated.
Specimen Requirements
To learn more about genetic counseling services, please
speak to your Integrated Genetics sales representative or call
855-GC-CALLS (855-422-2557) to obtain additional information.
Whole Blood
 Use only the black and tan capped blood
collection tubes from the informaSeq kit
 One
Streck tube, minimum 7 mL
 Store
samples at room temperature and
transport at ambient temperature in the
informaSeq kit
Affordable Payment Options for Your Patients
Insurance
Integrated Genetics is contracted with over 400 healthcare plans,
helping patients maximize their benefits
Patient specific programs
Payment plans, special payment plans for financial hardship,
and indigent requests from a physician or clinical facility
Medicare/Medicaid
Integrated Genetics accepts both Medicare and Medicaid
and will bill these programs on the patient’s behalf
Integrated Genetics – a leading
provider of reproductive genetic testing
services, driven by its commitment to
physicians and patients. Learn more by
visiting www.integratedgenetics.com
or calling Integrated Genetics Client
Services at 800-848-4436.
Turnaround Time:
 5 -7 business days
A test your patients can trust. A company you know and trust.
informaSeq SM Prenatal Test is Powered by Illumina®
sequencing technology.
informaSeqSM Prenatal Test – an advanced, non-invasive, next generation prenatal
screening for T21, T18, and T13 chromosomal aneuploidies. When you recommend
informaSeq, you’re choosing a trusted partner.
Please call us toll-free at 800-845-6167 for any billing questions.
We are available between the hours of 8:00 AM and 5:00 PM, Monday through Friday.
informaSeq , SequentialScreen SM, IntegratedScreen SM, and Serum IntegratedScreen SM are
service marks of Laboratory Corporation of America ® Holdings.
FirstScreen ® and Afp4® are registered service marks of Laboratory Corporation of America ® Holdings.
Powered by Illumina ® is a trademark of Illumina, Inc. in the U.S. and/or other countries
©2014 Laboratory Corporation of America ® Holdings. All rights reserved.
rep-880-v2-0914
L13272-0914-2
SM
www.mytestingoptions.com
www.integratedgenetics.com
From a Company You Know
You Can Trust
informaSeqSM Prenatal Test
Answers Your Patients Can Trust
P
Reliable results support informed decision making.
rovide your patients with a precise, non-invasive test that can assess
risk for multiple fetal chromosomal aneuploidies from a single blood draw.
Simple and safe, informaSeq can be administered as early as 10 weeks,
giving you and your patients the information you both need.
When you recommend prenatal testing for your patients, you can do so with confidence in
our company, our laboratory, and the test. informaSeq’s high detection rates (sensitivity) and
low false positive rates (specificity) for common chromosomal and sex aneuploidies provide
reliable answers you and your patients can trust.
Predictive Values2,3
Intended Use
informaSeq is intended for patients with
singleton, twin, and donor pregnancies as
early as 10 weeks gestation who meet any
of the following criteria:
 Advanced
maternal age (≥35 years
for singleton and twin pregnancies)
 Positive
serum screen
 Abnormal
ultrasound
 Increased
risk of T21, T18, T13
(or sex chromosome aneuploidy
in singleton pregnancy)
]
ACOG and Society of
Maternal Fetal Medicine
(SMFM) Committee recognized
the tremendous potential
of cell-free DNA (cfDNA)
testing and concluded that
cfDNA testing can be offered
to informed patients at
increased risk of aneuploidy.1
Positive
Predictive Value
Negative
Predictive Value
21
99.4%
99.9%
18
91.0%
99.9%
13
84.3%
99.9%
Sensitivity
The basic informaSeq test
screens for:
Optional testing detects:
 Monosomy
(Down syndrome)
 X XX
(Triple X)
 T18
(Edwards syndrome)  X XY
(Klinefelter syndrome)
 T13
(Patau syndrome)
 X YY
(Jacobs syndrome)
sex (XX or XY) – aids in stratifying
the risk for X-linked disorders such as
hemophilia

ANEUPLOIDY
SUSPECTED
NOT DETECTED
Yes





Sensitivity
Specificity
99.8%
MX
95.0%
99.0%
99.6%
XX
97.6%
99.2%
>99.9%
XY
99.1%
98.9%
XXX
XXY
XYY
These are more rare aneuploidies
with limited data, precluding
performance calculations.
97.4%
13
87.5%
Sex chromosome mosaicism cannot be
distinguished by this method (the occurrence
of which is <0.3%).
 Fetal
REFERENCES
1.Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 120:1532-4.
2.Futch, T, Spinosa J, Bhatt, S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma
DNA samples. Prenat Diagn 2013:33-569-574.
3.Based on internal correlation data.
4.Verinata Health, Inc. (2012) analytical validation of the verifi® Prenatal Test: Enhanced Test Performance For Detecting Trisomies 21, 18, 13 and the Option for Classification
of Sex Chromosome Status. Redwood City, CA.
5.ACOG Practice Bulletin 77. Screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109:217-227.
www.mytestingoptions.com
Counsel the patient about
informaSeq prenatal test
and diagnostic test options.
Counsel the patient about
the informaSeq prenatal test,
its risks and limitations, and
diagnostic test options.
No
Does the patient elect testing?
Counsel the patient about testing
options per ACOG Practice
Bulletin, Screening for Fetal
Chromosomal Abnormalities.5
Yes
Serum Screening
(per practice’s protocol)
CVS/Amniocentesis
(Diagnostic)
Genetic Counseling
is an appropriate
option
Test performance in the most common
sex chromosomes4
Specificity
No


>99.9%
18
X (MX; Turner syndrome)
 T21
DETECTED
Is the patient at increased risk
for aneuploidy?
With any screening test, false positives
and false negatives can occur. However,
the informaSeq test provides context by
reporting a “highest risk” result as “aneuploidy
detected” and a lower risk, more borderline
result as “aneuploidy suspected”. You and
your patients may use these distinctions to
help determine the best next steps.
21
Testing for Trisomies 21, 18, and 13
Test Results
Test performance in the most common
chromosomal aneuploidies4
Please note: This test does not assess risk for
mosaicism, partial trisomies, or translocations.
When choosing a laboratory to perform important tests, it is also critical that the laboratory
have the capability to provide the necessary follow-up testing and/or counseling your
patients may require. Integrated Genetics is your lab for a full complement of reproductive
genetic screening and diagnostic options.
Yes
Is the serum screen
result increased risk?
Is the informaSeq
test result Aneuploidy
Detected or Suspected?
No
No
Yes
Yes
Does the
patient
elect testing?
No
Continue with pregnancy management according to your practice’s protocols.
Serum Screening Support for Your Practice Protocol
Trust Integrated Genetics to offer you the Right Test at the Right Time for your serum screening
needs. If serum screening is desired, you can choose from the following:
 First
trimester – FirstScreen®
 First
and second trimester combined – SequentialScreenSM, IntegratedScreenSM, and
Serum IntegratedScreenSM
 Second
trimester – Afp4®
www.integratedgenetics.com
From a Company You Know
You Can Trust
informaSeqSM Prenatal Test
Answers Your Patients Can Trust
P
Reliable results support informed decision making.
rovide your patients with a precise, non-invasive test that can assess
risk for multiple fetal chromosomal aneuploidies from a single blood draw.
Simple and safe, informaSeq can be administered as early as 10 weeks,
giving you and your patients the information you both need.
When you recommend prenatal testing for your patients, you can do so with confidence in
our company, our laboratory, and the test. informaSeq’s high detection rates (sensitivity) and
low false positive rates (specificity) for common chromosomal and sex aneuploidies provide
reliable answers you and your patients can trust.
Predictive Values2,3
Intended Use
informaSeq is intended for patients with
singleton, twin, and donor pregnancies as
early as 10 weeks gestation who meet any
of the following criteria:
 Advanced
maternal age (≥35 years
for singleton and twin pregnancies)
 Positive
serum screen
 Abnormal
ultrasound
 Increased
risk of T21, T18, T13
(or sex chromosome aneuploidy
in singleton pregnancy)
]
ACOG and Society of
Maternal Fetal Medicine
(SMFM) Committee recognized
the tremendous potential
of cell-free DNA (cfDNA)
testing and concluded that
cfDNA testing can be offered
to informed patients at
increased risk of aneuploidy.1
Positive
Predictive Value
Negative
Predictive Value
21
99.4%
99.9%
18
91.0%
99.9%
13
84.3%
99.9%
Sensitivity
The basic informaSeq test
screens for:
Optional testing detects:
 Monosomy
(Down syndrome)
 X XX
(Triple X)
 T18
(Edwards syndrome)  X XY
(Klinefelter syndrome)
 T13
(Patau syndrome)
 X YY
(Jacobs syndrome)
sex (XX or XY) – aids in stratifying
the risk for X-linked disorders such as
hemophilia

ANEUPLOIDY
SUSPECTED
NOT DETECTED
Yes





Sensitivity
Specificity
99.8%
MX
95.0%
99.0%
99.6%
XX
97.6%
99.2%
>99.9%
XY
99.1%
98.9%
XXX
XXY
XYY
These are more rare aneuploidies
with limited data, precluding
performance calculations.
97.4%
13
87.5%
Sex chromosome mosaicism cannot be
distinguished by this method (the occurrence
of which is <0.3%).
 Fetal
REFERENCES
1.Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 120:1532-4.
2.Futch, T, Spinosa J, Bhatt, S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma
DNA samples. Prenat Diagn 2013:33-569-574.
3.Based on internal correlation data.
4.Verinata Health, Inc. (2012) analytical validation of the verifi® Prenatal Test: Enhanced Test Performance For Detecting Trisomies 21, 18, 13 and the Option for Classification
of Sex Chromosome Status. Redwood City, CA.
5.ACOG Practice Bulletin 77. Screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109:217-227.
www.mytestingoptions.com
Counsel the patient about
informaSeq prenatal test
and diagnostic test options.
Counsel the patient about
the informaSeq prenatal test,
its risks and limitations, and
diagnostic test options.
No
Does the patient elect testing?
Counsel the patient about testing
options per ACOG Practice
Bulletin, Screening for Fetal
Chromosomal Abnormalities.5
Yes
Serum Screening
(per practice’s protocol)
CVS/Amniocentesis
(Diagnostic)
Genetic Counseling
is an appropriate
option
Test performance in the most common
sex chromosomes4
Specificity
No


>99.9%
18
X (MX; Turner syndrome)
 T21
DETECTED
Is the patient at increased risk
for aneuploidy?
With any screening test, false positives
and false negatives can occur. However,
the informaSeq test provides context by
reporting a “highest risk” result as “aneuploidy
detected” and a lower risk, more borderline
result as “aneuploidy suspected”. You and
your patients may use these distinctions to
help determine the best next steps.
21
Testing for Trisomies 21, 18, and 13
Test Results
Test performance in the most common
chromosomal aneuploidies4
Please note: This test does not assess risk for
mosaicism, partial trisomies, or translocations.
When choosing a laboratory to perform important tests, it is also critical that the laboratory
have the capability to provide the necessary follow-up testing and/or counseling your
patients may require. Integrated Genetics is your lab for a full complement of reproductive
genetic screening and diagnostic options.
Yes
Is the serum screen
result increased risk?
Is the informaSeq
test result Aneuploidy
Detected or Suspected?
No
No
Yes
Yes
Does the
patient
elect testing?
No
Continue with pregnancy management according to your practice’s protocols.
Serum Screening Support for Your Practice Protocol
Trust Integrated Genetics to offer you the Right Test at the Right Time for your serum screening
needs. If serum screening is desired, you can choose from the following:
 First
trimester – FirstScreen®
 First
and second trimester combined – SequentialScreenSM, IntegratedScreenSM, and
Serum IntegratedScreenSM
 Second
trimester – Afp4®
www.integratedgenetics.com
From a Company You Know
You Can Trust
informaSeqSM Prenatal Test
Answers Your Patients Can Trust
P
Reliable results support informed decision making.
rovide your patients with a precise, non-invasive test that can assess
risk for multiple fetal chromosomal aneuploidies from a single blood draw.
Simple and safe, informaSeq can be administered as early as 10 weeks,
giving you and your patients the information you both need.
When you recommend prenatal testing for your patients, you can do so with confidence in
our company, our laboratory, and the test. informaSeq’s high detection rates (sensitivity) and
low false positive rates (specificity) for common chromosomal and sex aneuploidies provide
reliable answers you and your patients can trust.
Predictive Values2,3
Intended Use
informaSeq is intended for patients with
singleton, twin, and donor pregnancies as
early as 10 weeks gestation who meet any
of the following criteria:
 Advanced
maternal age (≥35 years
for singleton and twin pregnancies)
 Positive
serum screen
 Abnormal
ultrasound
 Increased
risk of T21, T18, T13
(or sex chromosome aneuploidy
in singleton pregnancy)
]
ACOG and Society of
Maternal Fetal Medicine
(SMFM) Committee recognized
the tremendous potential
of cell-free DNA (cfDNA)
testing and concluded that
cfDNA testing can be offered
to informed patients at
increased risk of aneuploidy.1
Positive
Predictive Value
Negative
Predictive Value
21
99.4%
99.9%
18
91.0%
99.9%
13
84.3%
99.9%
Sensitivity
The basic informaSeq test
screens for:
Optional testing detects:
 Monosomy
(Down syndrome)
 X XX
(Triple X)
 T18
(Edwards syndrome)  X XY
(Klinefelter syndrome)
 T13
(Patau syndrome)
 X YY
(Jacobs syndrome)
sex (XX or XY) – aids in stratifying
the risk for X-linked disorders such as
hemophilia

ANEUPLOIDY
SUSPECTED
NOT DETECTED
Yes





Sensitivity
Specificity
99.8%
MX
95.0%
99.0%
99.6%
XX
97.6%
99.2%
>99.9%
XY
99.1%
98.9%
XXX
XXY
XYY
These are more rare aneuploidies
with limited data, precluding
performance calculations.
97.4%
13
87.5%
Sex chromosome mosaicism cannot be
distinguished by this method (the occurrence
of which is <0.3%).
 Fetal
REFERENCES
1.Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 120:1532-4.
2.Futch, T, Spinosa J, Bhatt, S, de Feo E, Rava RP, Sehnert AJ. Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma
DNA samples. Prenat Diagn 2013:33-569-574.
3.Based on internal correlation data.
4.Verinata Health, Inc. (2012) analytical validation of the verifi® Prenatal Test: Enhanced Test Performance For Detecting Trisomies 21, 18, 13 and the Option for Classification
of Sex Chromosome Status. Redwood City, CA.
5.ACOG Practice Bulletin 77. Screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109:217-227.
www.mytestingoptions.com
Counsel the patient about
informaSeq prenatal test
and diagnostic test options.
Counsel the patient about
the informaSeq prenatal test,
its risks and limitations, and
diagnostic test options.
No
Does the patient elect testing?
Counsel the patient about testing
options per ACOG Practice
Bulletin, Screening for Fetal
Chromosomal Abnormalities.5
Yes
Serum Screening
(per practice’s protocol)
CVS/Amniocentesis
(Diagnostic)
Genetic Counseling
is an appropriate
option
Test performance in the most common
sex chromosomes4
Specificity
No


>99.9%
18
X (MX; Turner syndrome)
 T21
DETECTED
Is the patient at increased risk
for aneuploidy?
With any screening test, false positives
and false negatives can occur. However,
the informaSeq test provides context by
reporting a “highest risk” result as “aneuploidy
detected” and a lower risk, more borderline
result as “aneuploidy suspected”. You and
your patients may use these distinctions to
help determine the best next steps.
21
Testing for Trisomies 21, 18, and 13
Test Results
Test performance in the most common
chromosomal aneuploidies4
Please note: This test does not assess risk for
mosaicism, partial trisomies, or translocations.
When choosing a laboratory to perform important tests, it is also critical that the laboratory
have the capability to provide the necessary follow-up testing and/or counseling your
patients may require. Integrated Genetics is your lab for a full complement of reproductive
genetic screening and diagnostic options.
Yes
Is the serum screen
result increased risk?
Is the informaSeq
test result Aneuploidy
Detected or Suspected?
No
No
Yes
Yes
Does the
patient
elect testing?
No
Continue with pregnancy management according to your practice’s protocols.
Serum Screening Support for Your Practice Protocol
Trust Integrated Genetics to offer you the Right Test at the Right Time for your serum screening
needs. If serum screening is desired, you can choose from the following:
 First
trimester – FirstScreen®
 First
and second trimester combined – SequentialScreenSM, IntegratedScreenSM, and
Serum IntegratedScreenSM
 Second
trimester – Afp4®
www.integratedgenetics.com
Help patients get answers and support for complex questions
with a trusted partner in genetic testing and counseling.
Access to Expert Genetic Counseling
Integrated Genetics has the largest national genetic counseling network. We offer both
in-person and easy access telegenetic genetic counseling that allows patients to interact
directly and “face-to-face” with our genetic counselors. Our counselors take complex genetic
data and turn it into practical, understandable, information and options, which can help
in making important, highly personal healthcare choices.
From a Company You Know and Trust
informaSeq, an advanced and accurate prenatal test
prenatal testing directed by board-certified molecular geneticists as early as
10 weeks’ gestational age
 Accurate
 Testing
performed via deep sequencing, which increases detection, even in samples with
a lower fraction of fetal DNA fragments
 Dual
Threshold resulting stratifies risk prediction
 Quick
resulting – 5-7 business days
Genetic counseling, to give your patients vital information
Genetic Risk Assessment
Patient Education
Patient Information
Coordinated
Patient Care
We evaluate reproductive and family history, review test results
and medical records, and identify genetic risk factors that can
affect the patient or offspring.
 More
We address any identified genetic risk factors, discuss the
disorder in question, including etiology, heritability, and clinical
implications, and explain testing and procedure options.
Integrated Genetics, an experienced partner
than 140 Integrated Genetics Genetic Counselors to help patients review results,
identify risk factors, and make more informed decisions
 Convenient
 Over
 A
We support the decision-making process by providing patients
clinical information and referrals to community resources.
Telegenetic Counseling services providing access for more patients
25 years of genetic testing expertise
complete menu of screening and diagnostic tests focused on women’s reproductive health
 Contracts
 Over
with more than 400 payors nationwide
1,700 patient service centers for convenient access to sample collection
We provide a summary report to the referring physician and
follow-up genetic counseling if indicated.
Specimen Requirements
To learn more about genetic counseling services, please
speak to your Integrated Genetics sales representative or call
855-GC-CALLS (855-422-2557) to obtain additional information.
Whole Blood
 Use only the black and tan capped blood
collection tubes from the informaSeq kit
 One
Streck tube, minimum 7 mL
 Store
samples at room temperature and
transport at ambient temperature in the
informaSeq kit
Affordable Payment Options for Your Patients
Insurance
Integrated Genetics is contracted with over 400 healthcare plans,
helping patients maximize their benefits
Patient specific programs
Payment plans, special payment plans for financial hardship,
and indigent requests from a physician or clinical facility
Medicare/Medicaid
Integrated Genetics accepts both Medicare and Medicaid
and will bill these programs on the patient’s behalf
Integrated Genetics – a leading
provider of reproductive genetic testing
services, driven by its commitment to
physicians and patients. Learn more by
visiting www.integratedgenetics.com
or calling Integrated Genetics Client
Services at 800-848-4436.
Turnaround Time:
 5 -7 business days
A test your patients can trust. A company you know and trust.
informaSeq SM Prenatal Test is Powered by Illumina®
sequencing technology.
informaSeqSM Prenatal Test – an advanced, non-invasive, next generation prenatal
screening for T21, T18, and T13 chromosomal aneuploidies. When you recommend
informaSeq, you’re choosing a trusted partner.
Please call us toll-free at 800-845-6167 for any billing questions.
We are available between the hours of 8:00 AM and 5:00 PM, Monday through Friday.
informaSeq , SequentialScreen SM, IntegratedScreen SM, and Serum IntegratedScreen SM are
service marks of Laboratory Corporation of America ® Holdings.
FirstScreen ® and Afp4® are registered service marks of Laboratory Corporation of America ® Holdings.
Powered by Illumina ® is a trademark of Illumina, Inc. in the U.S. and/or other countries
©2014 Laboratory Corporation of America ® Holdings. All rights reserved.
rep-880-v2-0914
L13272-0914-2
SM
www.mytestingoptions.com
www.integratedgenetics.com
Help patients get answers and support for complex questions
with a trusted partner in genetic testing and counseling.
Access to Expert Genetic Counseling
Integrated Genetics has the largest national genetic counseling network. We offer both
in-person and easy access telegenetic genetic counseling that allows patients to interact
directly and “face-to-face” with our genetic counselors. Our counselors take complex genetic
data and turn it into practical, understandable, information and options, which can help
in making important, highly personal healthcare choices.
From a Company You Know and Trust
informaSeq, an advanced and accurate prenatal test
prenatal testing directed by board-certified molecular geneticists as early as
10 weeks’ gestational age
 Accurate
 Testing
performed via deep sequencing, which increases detection, even in samples with
a lower fraction of fetal DNA fragments
 Dual
Threshold resulting stratifies risk prediction
 Quick
resulting – 5-7 business days
Genetic counseling, to give your patients vital information
Genetic Risk Assessment
Patient Education
Patient Information
Coordinated
Patient Care
We evaluate reproductive and family history, review test results
and medical records, and identify genetic risk factors that can
affect the patient or offspring.
 More
We address any identified genetic risk factors, discuss the
disorder in question, including etiology, heritability, and clinical
implications, and explain testing and procedure options.
Integrated Genetics, an experienced partner
than 140 Integrated Genetics Genetic Counselors to help patients review results,
identify risk factors, and make more informed decisions
 Convenient
 Over
 A
We support the decision-making process by providing patients
clinical information and referrals to community resources.
Telegenetic Counseling services providing access for more patients
25 years of genetic testing expertise
complete menu of screening and diagnostic tests focused on women’s reproductive health
 Contracts
 Over
with more than 400 payors nationwide
1,700 patient service centers for convenient access to sample collection
We provide a summary report to the referring physician and
follow-up genetic counseling if indicated.
Specimen Requirements
To learn more about genetic counseling services, please
speak to your Integrated Genetics sales representative or call
855-GC-CALLS (855-422-2557) to obtain additional information.
Whole Blood
 Use only the black and tan capped blood
collection tubes from the informaSeq kit
 One
Streck tube, minimum 7 mL
 Store
samples at room temperature and
transport at ambient temperature in the
informaSeq kit
Affordable Payment Options for Your Patients
Insurance
Integrated Genetics is contracted with over 400 healthcare plans,
helping patients maximize their benefits
Patient specific programs
Payment plans, special payment plans for financial hardship,
and indigent requests from a physician or clinical facility
Medicare/Medicaid
Integrated Genetics accepts both Medicare and Medicaid
and will bill these programs on the patient’s behalf
Integrated Genetics – a leading
provider of reproductive genetic testing
services, driven by its commitment to
physicians and patients. Learn more by
visiting www.integratedgenetics.com
or calling Integrated Genetics Client
Services at 800-848-4436.
Turnaround Time:
 5 -7 business days
A test your patients can trust. A company you know and trust.
informaSeq SM Prenatal Test is Powered by Illumina®
sequencing technology.
informaSeqSM Prenatal Test – an advanced, non-invasive, next generation prenatal
screening for T21, T18, and T13 chromosomal aneuploidies. When you recommend
informaSeq, you’re choosing a trusted partner.
Please call us toll-free at 800-845-6167 for any billing questions.
We are available between the hours of 8:00 AM and 5:00 PM, Monday through Friday.
informaSeq , SequentialScreen SM, IntegratedScreen SM, and Serum IntegratedScreen SM are
service marks of Laboratory Corporation of America ® Holdings.
FirstScreen ® and Afp4® are registered service marks of Laboratory Corporation of America ® Holdings.
Powered by Illumina ® is a trademark of Illumina, Inc. in the U.S. and/or other countries
©2014 Laboratory Corporation of America ® Holdings. All rights reserved.
rep-880-v2-0914
L13272-0914-2
SM
www.mytestingoptions.com
www.integratedgenetics.com